Evidence map›Paper›PMID 36737697›Full record

ArticleBMC pulmonary medicine2023

Lung function and collagen 1a levels are associated with changes in 6 min walk test distance during treatment of TB among HIV-infected adults: a prospective cohort study.

Yeonsoo Baik, Pholo Maenetje, Diana Schramm, Caroline Tiemessen, Itai Ncube, Gavin Churchyard, Robert Wallis, Mboyo-di-Tamba Vangu, Hardy Kornfeld, Yun Li and 2 more

Abstract read
In one paragraph

Article in BMC pulmonary medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Yeonsoo BaikDepartment of Biostatistics, Epidemiology, and Informatics, Center for Clinical Epidemiology and Biostatistics, Perelman School of Medicine at the University of Pennsylvania, 832 Blockley Hall, 423 Guardian Drive, Philadelphia, PA, 19104-6021, USA.
Pholo MaenetjeThe Aurum Institute, Johannesburg, South Africa.
Diana SchrammDepartment of Virology, Faculty of Health Sciences, School of Pathology, University of the Witwatersrand, Johannesburg, South Africa.
Caroline TiemessenDepartment of Virology, Faculty of Health Sciences, School of Pathology, University of the Witwatersrand, Johannesburg, South Africa.
Itai NcubeThe Aurum Institute, Johannesburg, South Africa.
Gavin ChurchyardThe Aurum Institute, Johannesburg, South Africa.
Robert WallisThe Aurum Institute, Johannesburg, South Africa.
Mboyo-di-Tamba VanguDepartment of Nuclear Medicine, CM Johannesburg Academic Hospital, University of the Witwatersrand, Johannesburg, South Africa.
Hardy KornfeldDepartment of Medicine, University of Massachusetts Chan Medical School, Worcester, USA.
Yun LiDepartment of Biostatistics, Epidemiology, and Informatics, Center for Clinical Epidemiology and Biostatistics, Perelman School of Medicine at the University of Pennsylvania, 832 Blockley Hall, 423 Guardian Drive, Philadelphia, PA, 19104-6021, USA.
Sara C Auld *Department of Medicine, Emory University Rollins School of Public Health and School of Medicine, Atlanta, GA, USA.
Gregory P Bisson *Department of Biostatistics, Epidemiology, and Informatics, Center for Clinical Epidemiology and Biostatistics, Perelman School of Medicine at the University of Pennsylvania, 832 Blockley Hall, 423 Guardian Drive, Philadelphia, PA, 19104-6021, USA. bisson@pennmedicine.upenn.edu.

Funding

Virology and Molecular Biomarkers CoreP30AI050409 · NIAID · EMORY UNIVERSITY · PI Ann M Chahroudi, Colleen F Kelley · 2002 to 2026
$74.0M
Emory/Georgia TB Research Advancement Center (TRAC)P30AI168386 · NIAID · EMORY UNIVERSITY · PI Jeffrey M Collins · 2022 to 2026
$5.8M
Rapid Immune Restoration and Lung Injury in HIV/TBR01AI120821 · NIAID · UNIVERSITY OF PENNSYLVANIA · PI BISSON, GREGORY P. · 2015 to 2019
$3.3M
NIAID NIH HHS P30 AI050409NIAID NIH HHS P30 AI168386NIAID NIH HHS R01 AI120821NIH HHS P30AI04500823NIH HHS R01AI120821
6 · The paper itself

Abstract

backgroundPatients with tuberculosis (TB) and HIV often present with impairments in lung function and exercise capacity after treatment. We evaluated clinical and immunologic variables associated with a minimum clinically important difference (MCID) in the change in the 6 min walk test distance during the first 24 weeks of antiretroviral (ART) and anti-tubercular therapy.

methodsAdults initiating ART and anti-TB treatment in the setting of newly-diagnosed HIV and pulmonary TB were enrolled in a prospective cohort study in South Africa. Patients underwent 6 min walk tests and spirometry at weeks 0, 4, 12, and 24 and biomarker level measurements early during treatment, at weeks 0, 4, and 12, when inflammation levels are typically elevated. Biomarkers included matrix metalloproteinases-1 (MMP-1), tissue inhibitor of MMP (TIMP)-1, collagen 1a, IL-6, IL-8, vascular cell adhesion molecule 1 (VCAM-1), C-X-C motif chemokine 10 (CXCL-10), CXCL-11, macrophage colony-stimulating factor (M-CSF), plasminogen activator, vascular endothelial growth factor, and chemokine (C-C) motif-2 (CCL-2). An MCID was derived statistically, and achievement of an MCID was modeled as the outcome using logistic regression model.

resultsEighty-nine patients walked an average of 393 (± standard deviation = 69) meters at baseline, which increased by an average of 9% (430 ± 70 m) at week 24. The MCID for change in walk distance was estimated as 41 m. Patients experiencing an MCID on treatment had worse lung function, lower 6 min walk test distance, higher levels of proinflammatory biomarkers including TIMP-1 and M-CSF, and lower levels of collagen 1a at baseline. Experiencing an MCID during treatment was associated with increases in forced expiratory volume in 1-s [odds ratio (OR) = 1.17, 95% confidence interval (CI) = 1.05-1.33] and increases in blood collagen 1a levels (OR = 1.31, 95%CI 1.06-1.62).

conclusionsART and TB treatment are associated with substantial improvements in 6 min walk test distance over time. Achievement of an MCID in the 6 min walk test in this study was associated with more severe disease at baseline and increases in collagen 1a levels and lung function during therapy.

Indexed as

HIV InfectionsTuberculosisAdultBiomarkersHumansLungMacrophage Colony-Stimulating FactorProspective StudiesVascular Endothelial Growth Factor AWalk TestBiomarkersMacrophage Colony-Stimulating FactorVascular Endothelial Growth Factor AHIV/TBInflammatory biomarkersPost-treatmentSix-minute walk testTuberculosis

Identifiers

PMID36737697
PMCPMC9896708

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.